| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2048342 | FEBS Letters | 2011 | 5 Pages |
Our previous study demonstrates that HER-2/Neu oncogene inhibits a matrix metalloproteinase inhibitor and tumor metastasis suppressor RECK to promote metastasis. Conversely, the effect of RECK on the oncogenic function of HER-2/Neu is unknown. Ectopic expression of RECK in 293T cells and HER-2/Neu-overexpressing breast cancer cells shows that RECK and HER-2/Neu are co-localized and these two proteins can be co-immunoprecipitated. RECK inhibits HER-2/Neu receptor dimerization and autophosphorylation, which causes reduction of ERK and AKT kinase activity and down-regulation of HER-2/Neu target genes. RECK expression is reduced in 58.8% of breast cancer tissues and is associated with lymph node invasion supporting its anti-metastatic role. Collectively, we provide the first evidence that RECK can negatively regulate oncogenic activity of HER-2/Neu by inhibiting receptor dimerization.Structured summaryHER-2/Neuphysically interacts with HER-2/Neu by blue native page (View interaction)HER-2/Neuphysically interacts with RECK by coimmunoprecipitation (View interaction)HER-2/Neu and RECKcolocalize by fluorescence microscopy (View Interaction 1, 2)HER-2/Neuphysically interacts with RECK by anti bait coimmunoprecipitation (View interaction)
